I’m away in Scotland of all places so don’t hear immediately the news. But what I am seeing is that we are only being chased by one suitor. This is in spite of proven and endorsed diagnostic certification by European CE Mark and Australian TGA. These certifications don’t come from the bottom of a Corn Flakes packet. No, they are earned through proof of clinical trials for pneumonia, bronchitis, COPD, asthma, and now potentially COVID. Pfizer is all over the amazing opportunity to pick us up, lock, stock and barrel for their chump change. Rounding error money.
Senior management for months, even years have been titillating LT shareholders with meaningful discussion promises. There have been executive hires in the UK. There are clinical studies within the NHS in eastern England. There have been studies with a German private hospital company. Even the French Health Minister quoted us as being helpful in the respiratory system.
So where is the meaningful interest for us? Many of us quoted the likes of Apple, Microsoft, AstraZenica, Johnson and Johnson, Ping An, and many others as being meaningful partners, unlocking the disruptive nature of our algos. They work, right? We know they do, and CEO Tony Keating goes on podcasts bleating how we have these ‘meaningful’ discussions with potential partners.
We seem to be AT LEAST THE EQUAL of the various Rapid Antigen Tests on the market and no doubt Pfizer will attempt to rip this from shareholders dreams and expectations so they can make a KILLING in the diagnostic market for Covid. Pfizer will throw us shareholders the equivalent of swill at a valuation of not much more than$120 million.
Where are Doctors on Demand? COVIU? The deal with Asthma Australia? The peer reviewed papers amongst the scientific community demonstrating the successful nature of this disruptive tech?
I have been fed a monthly diet of disruption, meaningful talks, 99% success with Experian in getting FDA, more meaningful talks, Fuching Sleep Check and it’s imminent FDAapproval. Leedman stating it will rake in more revenue than Dx.
Perhaps games are still being played by the big end of global health. Perhaps others will pounce. But the deafening silence of anything meaningful to counter the offal currently presented to us is crushing the belief we had for our ‘leaders’.
Keating and Leedman, this is the time to make your mark, bring in a deal that justifies the brilliant mind of Professor Abeyratne and the justification of your very existence and titles of ‘senior management’.
Make this work, because it is more than a dream. We are way over any piffling dream: this is becoming a disaster of inadequate leadership. Inadequate appointments with various expert boards, and the BOD. This should be much more than what we have now. This is Nobel Prize stuff. Life saving reality that is fast falling away into virtually nothing.
If this isn’t remedied in the not too distant future, this will go down as the biggest failure of a winning disruptive gift to the medical world. And the names that will echo around the empty offices of ResApp Health will be Keating, Leedman and Chairman Aston. Why haven’t you shown up front leadership Mr Chairman? Are you capable of leading from the front? From where I’m observing you don’t even exist, yet you are the CHAIRMAN OF THE BOARD! To quote Paul Keating, this group of leaders are pissants.
I will be the first to apologise for this rant if I am given the means to warrant it. Those means are a full and meaningful buyout, or better still, a partnership with a global player that can take you out of the corporate sandpit. This company deserves a SP of north of $1. Make it happen, please, for the realisation of hundreds of retail shareholders dreams and aspirations. We have had strong belief in you. Well now is the time to show us you are worthy of our trust.
Expand
